Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hikma Highlights Long-Term Importance Of Biosimilars

CEO Siggi Olafsson Discusses The Evolution Of Hikma’s Injectables Business

24 Jan 2022

• By Dave Wallace

Timeline years 2025 blue pin — Hikma sees biosimilars becoming a significant part of its business from 2025 • Source: Olivier Le Moal / Alamy Stock Photo

Related Content

Hikma Buys Teligent Assets To Expand Into Canada

17 Jan 2022

Hikma Is Taking Another Look At US Biosimilars

10 Mar 2021

Hikma’s US Biosimilars Ambitions Begin With $150m Ustekinumab Deal

27 Aug 2021

Hikma Builds On US Biosimilar Ambitions With Deal For Richter’s Denosumab

09 Dec 2021

Related Companies

Hikma Pharmaceuticals plc

Additional Topics

United States Biosimilars Strategy Deals BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.